UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
null
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
null
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
null
How UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) Investors
null
Sector Update: Healthcare Stocks Gain Late Afternoon
null
UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says
null
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
null
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
null
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
null
Assessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch Momentum
null
Urogen Pharma Q1 Earnings Call Highlights
null
UroGen Pharma Ltd. Q1 2026 Earnings Call Summary
null
UroGen (URGN) Q1 2026 Earnings Transcript
null
UroGen Pharma to Present at Upcoming Investor Conferences
null
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
null
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates
null
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
null
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
null
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
null
Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady
null
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
null
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
null
How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities
null
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
null
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
null
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish
null
UroGen refinances debt with $250M facility at 8.25% rate
null
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
null
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
null
UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push
#Product Stage #Investment
UroGen Pharma Ltd. Q4 2025 Earnings Call Summary
null
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
#Product Stage #Investment
Urogen Pharma Q4 Earnings Call Highlights
#Product Stage #Customers #Investment
UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...
#Product Stage #Investment
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
#PIPE/PO #Partners
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
undefined
UroGen (URGN) Q4 2025 Earnings Call Transcript
#Product Stage #Investment #FDA approved/pending approval
A Look At UroGen Pharma (URGN) Valuation After New Phase 3 ENVISION ZUSDURI Data
#Product Stage
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
#Product Stage
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
undefined
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
undefined
UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target
#Product Stage #FDA approved/pending approval #Expand
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
#Product Stage #FDA approved/pending approval
UroGen Pharma says permanent J Code for ZUSDURI now in effect
undefined
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
#Product Stage #Customers
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term
undefined
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally
undefined
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
undefined
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs
#Product Stage #Expand
Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report
undefined
Why UroGen Pharma (URGN) Is Up 15.0% After FDA Backs UGN-103 and Reports Strong Trial Results
#Product Stage #Customers
UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
#Product Stage #Expand
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
#Product Stage #FDA approved/pending approval
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
undefined
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
#Product Stage #Customers
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
undefined
Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates
undefined
Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
undefined
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
#Public Trading
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
undefined
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
#Product Stage #FDA approved/pending approval
MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last?
#Product Stage
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
#Product Stage
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
UroGen Pharma to Present at Upcoming Investor Conferences
undefined
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
undefined
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...
#Product Stage #Expand
Sector Update: Health Care Stocks Decline Late Afternoon
undefined
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
#Product Stage #FDA approved/pending approval
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
undefined
UroGen’s Zusduri benefit maintained in NMIBC Phase III study
#Product Stage
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
#Product Stage
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
undefined
UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology
#Product Stage #FDA approved/pending approval
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
undefined
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
#Product Stage
High Growth Tech Stocks In The US Market
#Product Stage #FDA approved/pending approval
UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future
undefined
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
#Product Stage
UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer
#Product Stage #Partners
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
#Product Stage #Partners
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer
#Product Stage #FDA approved/pending approval
H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy
#Product Stage #FDA approved/pending approval
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
#Partners #Investment
High Growth Tech Stocks in US for June 2025
#Product Stage #FDA approved/pending approval
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
#Product Stage #FDA approved/pending approval
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
#Product Stage #FDA approved/pending approval
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
#Product Stage #FDA approved
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
undefined
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
#Product Stage #FDA approved/pending approval
Biotech Alert: Searches spiking for these stocks today
#Product Stage
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target Price
undefined
UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...
#Product Stage #Expand
Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates
undefined
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
#Product Stage #FDA approved/pending approval
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
#Product Stage
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
undefined
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?
undefined
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
#Product Stage #FDA approved/pending approval
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
#Product Stage
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
#Product Stage
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
#Product Stage
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
#Product Stage
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
#Product Stage #Public Trading
High Growth Tech Stocks In The US To Watch April 2025
undefined
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...
#Product Stage #Expand
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
undefined
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
#Product Stage #Acquisition
Exploring High Growth Tech Stocks in the US Market
#FDA approved/pending approval #Customers #Product Stage
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
undefined
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?
undefined
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
null
UroGen acquires IconOVir’s oncolytic virus assets
#Acquisition #Partners
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
#Acquisition #Partners
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
#Product Stage
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
#Product Stage
UroGen Pharma to Present at Upcoming Investor Conferences
null
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
undefined
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
#Product Stage
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)
undefined
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
null
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
undefined
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
undefined
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
undefined
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade
undefined
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment
undefined
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
undefined
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target
undefined
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
#Customers
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates
undefined
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
undefined
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
null
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
null
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
undefined
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years
undefined
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment
undefined
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
null
UroGen Appoints Chris Degnan as Chief Financial Officer
null
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
#Public Trading #Expand
UroGen begins subject dosing in Phase III bladder cancer drug trial
undefined
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
null
UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock
#Investment
UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now
#Investment
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
null
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
null
UroGen Pharma to Present at Upcoming Investor Conferences
null
UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88
#Investment
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
null
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
#Investment
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
null
Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline
#Investment, Management Changes
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
null
Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?
#Investment
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
#Investment
Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
#Public Trading
UroGen Pharma Stock Earns 91 RS Rating
null
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
null
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
null
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
#Investment
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
#Public Trading #Investment
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
null
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
#Investment
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
null
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
null
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
null
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
null
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
null
UroGen Pharma First Quarter 2024 Earnings: Misses Expectations
#Customers
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
null
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
#Investment
Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
#Customers
UroGen Pharma to Participate at Upcoming Investor Conferences
null
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
null
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
null
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
null
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
null
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
#Customers #Expand
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
null
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
null
UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
#Investment
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
null
UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
#Customers
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript
#Investment #Expand
UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges
#Customers #Investment
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
#Investment
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
null
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
null
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
null
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
null
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
#Investment
UroGen Pharma to Participate at Upcoming Investor Conferences
null
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
null
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
null
UroGen Pharma to Participate in the B. Riley Healthcare Conference
null
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
null
Shareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years ago
#Public Trading
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript
#Customers #Investment
UroGen Pharma Reports Third Quarter 2023 Financial Results
null
UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials
#Customers
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
null
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
null
Institutional investors own a significant stake of 50% in UroGen Pharma Ltd. (NASDAQ:URGN)
#Investment
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
undefined
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
UroGen Pharma to Present at Upcoming Investor Conferences
#Investment #Expand
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
#Customers
New Treatment for Bladder Cancer Offers This Biotech a Second Chance
#Customers #Investment
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript
#Investment #Expand
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
#Investment #Expand
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
#Investment
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet
#Investment
The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
#Investment, Expand
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
#Public Trading
‘Opportunities Outweigh Risks’: Oppenheimer Sees at Least 60% Gains in These 2 Stocks
#Investment, Customers
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Management Changes
Biotech Firm To Raise $120M After Promising Cancer Drug Trials
#Investment
Why Shares of UroGen Pharma Jumped Friday
#Investment
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
#Investment
UroGen Announces $120 Million Private Placement of Ordinary Shares
#Investment
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
#Management Changes #Expand
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
#Customers
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
undefined
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
undefined
UroGen Pharma to Present at Upcoming Investor Conferences
undefined
With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns
#Investment
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript
#Customers #Management Changes
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
undefined
Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates
undefined
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
undefined
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline
undefined
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
undefined
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
undefined
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
undefined
UroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift Shares
undefined
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call Transcript
#Customers #Investment
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
undefined
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
undefined
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
undefined
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
undefined
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
undefined
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
undefined
UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future
undefined
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
undefined
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma's JELMYTO® Admixture to 96 Hours Following Reconstitution
undefined
UroGen Pharma Appoints Dr. Leana S. Wen to Board of Directors | citybiz
#Management Changes
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
undefined
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
undefined
UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel
undefined
UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments
undefined
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
undefined
"Exits are not a Strategy. I Never put up a 'For Sale' Sign"
#Investment #Public Trading
FDA approves UroGen's urothelial cancer drug
#Customers
Urogen buys new urinary tract cancer drug candidate
#Acquisition
Prof. Arie Belldegrun sees $1b market for UroGen drugs
#Customers
Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen
#Partners
Cancer co Urogen to raise $150m in Nasdaq offering
#Investment #Management Changes
Urogen reports positive Phase III urinary tract cancer drug results
#Customers #Investment
UroGen Pharma raises $60m in Nasdaq offering
#Public Trading #Partners
UroGen Pharma raises $58.2m in Nasdaq IPO
#Public Trading
UroGen Pharma sets terms for $45m Nasdaq IPO
#Public Trading
UroGen Pharma files for $50m Nasdaq IPO
#Public Trading
Bladder treatment co TheraCoat raises $7m
#Investment #Expand
Theracoat gel makes drugs stick to the bladder
#Customers